Chiesi Farmaceutici S.p.a.

Zambon S.p.a.

Università Degli Studi Di Parma

Chiesi Farmaceutical S.p.a.

Paolo Ventura

Paolo Chiesi

Gaetano Brambilla

David Andrew Lewis

Raffaella Garzia

Brian John Meakin

Vittorino Servadio

David Ganderton

Maurizio Del Canale

Gabriele Amari

Renato De Fanti

Paolo Colombo

Giovanni Caponetti

Rossella Musa

Daniela Acerbi

Ruggero Bettini

Roberto Bilzi

Josef Szejtli

Maria Vikmon

Pier Luigi Catellani

Claudio Pietra

Isabella Panza

Massimo Pasini

Davis Ganderton

Rosa Mezzadri

Roberto Pighi

Jan H Johansson

Elisabetta Armani

Maurizio Delcanale

Fausto Pivetti

Gino Villetti

Tore Curstedt

Loretta Maggi

Eva Fenyvesi

Marco Del Corno

Cristina Veneziani

Laura Zanellotti

Brian Meakin

Bluetta Salsi

Mario Varesco

Maurizio Redenti

Walter Recchia

Enrico Redenti

Stefano Cagnani

Hans Jörnvall

The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation in the form of powder comprising at least a first and a second powder, in which at least said first powder contains an active agent in an amount greater than 1% by weight with respect to the weight of said first powder. Both the powders comprise leucine in an amount ranging from 5 to 70% by weight with respect to the weight of each powder and a sugar in an amount ranging from 20 to 90% by weight with respect to the weight of each powder. The composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 80.

Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation

Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.

Pharmaceutical aerosol composition

The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is stainless steel, anodized aluminum, or lined with an inert organic coating and which contain a formulation which comprises ipratropium bromide.

Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining

The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

Pressurised metered dose inhalers (MDI)

The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the microparticles that allow the powder to flow and to be easy aerosolized. Typical dry powder of insulin described in this patent show corrugated, nonagglomerated microparticles with a low tapped density. The mean geometric diameter (particle size) ranges between 1.0 and 10.0 micron and the mass median aerodynamic diameter (MMAD) ranges between 1.0 and 4.0 micron. These insulin pulmonary powders exhibit in vitro a very high respirable fraction (&#x3e;75%).

Insulin highly respirable microparticles

A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.

Carrier particles, for use in the preparation of powdery mixtures for administration by inhalation, and having a median diameter of greater than 90 microns and a surface rugosity expressed as the fractal dimension of less than or equal to 1.1, may be prepared by subjecting particles having a median diameter of greater than 90 microns to repeated stages of wetting with a solvent and drying.

Powder particles with smooth surface for use in inhalation therapy

The invention relates to the use of pressurized metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminum or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

The invention relates to the use of pressurized metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodized aluminum or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.

Modified carrier particles for use in dry powder inhalers

SP-C analogue artificial peptides having surface activity are disclosed and their use for preparing artificial surfactants useful in the treatment of respiratory distress syndrome (RDS) and other diseases related to surfactant deficiency or dysfunction.

Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant

Carriers for use in the preparation of mixtures for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described.

In a solution composition for use in an aerosol inhaler which comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility compound the use of a mixture of HFA 134 and HFA 227 allows to modulate the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler to target specific regions of the respiratory tract. Moreover the fine particle dose (FPD) of the active ingredient in the composition increases by reducing the metering chamber volume.

Pharmaceutical aerosol composition containing HFA 227 and HFA 134a

A pharmaceutical formulation in the form of a fast dissolving tablet comprising an active ingredient, sodium glycine carbonate and an acid capable of reacting rapidly with sodium glycine carbonate to release carbon dioxide.

Pharmaceutical compositions containing an effervescent acid-base couple

Growing community of inventors

Parma, Italy

Paolo Ventura